NDAINJECTIONINJECTABLE
Approved
Apr 1952
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
ACTHAR GEL (repository corticotropin) by ANI Pharmaceuticals is unknown. Approved for exacerbations of multiple sclerosis in adults, acute exacerbations of multiple sclerosis in adults, multiple sclerosis and 3 more indications. First approved in 1952.
Drug data last refreshed 23h ago
Mechanism of Action
unknown. Acthar Gel and endogenous ACTH stimulate the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances. Prolonged administration of large doses of Acthar Gel induces hyperplasia and hypertrophy of the adrenal cortex and continuous high…
Pharmacologic Class:
Adrenocorticotropic Hormone
Indications (4)
Worked on ACTHAR GEL at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.